Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics

Last updated: March 17, 2025
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Overall Status: Active - Recruiting

Phase

N/A

Condition

Eczema (Atopic Dermatitis)

Dermatitis, Atopic

Atopic Dermatitis

Treatment

comprhensive spatial transcriptomic profile on lesional skin biopsies

Clinical Study ID

NCT06884163
7219
  • Ages 18-65
  • All Genders

Study Summary

The study explores the immune landscape of chronic hand eczema using spatial transcriptomics and single-cell proteomics, offering new insights into disease mechanisms and potential therapeutic targets.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients affected with chronic hand eczema of endogenous and/or exogenous origin,age from 18 to 65 years

  • Patients affected with eczema located on the hands for at least 3 months or with ≥ 2disease flare-ups in the last year.

  • Patients affected with atopic dermatitis affecting the hands and other areas of thebody, provided the eczema lesions involve less than 30% of the body surface area.

Exclusion

Exclusion Criteria:

  • Concurrent or previous treatment with immunosuppressants, except for short coursesof systemic corticosteroids (less than one month of continuous treatment), orbiologic agents that may affect the clinical aspects or progression of chronic handeczema.

  • Patients who have received systemic corticosteroids within one month prior toenrollment in the study.

  • Patients using topical corticosteroids or calcineurin inhibitors within one week ofstudy enrollment (this time frame is considered to provide a good balance betweenpotential residual pharmacological effects and ethical considerations).

  • Patients with chronic hand eczema of mixed etiology (e.g., allergic and atopic) orthose considered "etiologically unclassifiable" will not be included in the dataanalysis.

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: comprhensive spatial transcriptomic profile on lesional skin biopsies
Phase:
Study Start date:
January 13, 2025
Estimated Completion Date:
January 01, 2027

Study Description

Patients aged 18 to 65 affected with chronic hand eczema will be included in the study. As clinical practice, severity of chronic hand eczema will be evaluated by validated scores as HECSI, DLQI, and NRS itch. Moreover patch tests will be performed. Skin biopsies will also be performed to confirm the diagnosis.

This study utilizes spatial transcriptomics and single-cell spatial proteomics to analyze biopsies of chronic hand eczema. It aims to identify distinct inflammatory cell subgroups and molecular markers that define the immune landscape of chronic hand eczema.

By comparing endogenous (atopic dermatitis, dyshidrotic eczema, idiopathic forms) and exogenous (allergic/irritant) chronic hand eczema, the research wants to describe specific immune endotypes and potential therapeutic targets.

The study also includes idiopathic chronic hand eczema subtypes, such as pompholyx and hyperkeratotic eczema, to clarify immune profiling and improve treatment strategies. By identifying molecular signatures unique to each chronic hand eczema subtype, this research could lead to more personalized and effective therapies.

Connect with a study center

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, 00168
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.